No, Neuralink is not publicly traded. Retail investors can’t buy it in a normal brokerage account today, so the realistic alternatives are waiting for an IPO, looking at comparable public medical-device stocks, or—if accredited—private secondary markets.
No, Neuralink is not publicly traded. Retail investors can’t buy it in a normal brokerage account today, so the realistic alternatives are waiting for an IPO, looking at comparable public medical-device stocks, or—if accredited—private secondary markets.
Neuralink is one of the most closely watched private companies in the market because it sits at the intersection of neuroscience, medical devices, and Elon Musk’s brand of high-stakes ambition. The company is still pushing clinical trials forward, raising large private rounds, and expanding beyond its first Telepathy program into speech and vision restoration.
That combination keeps retail investors asking the same question: how do you actually invest in Neuralink if it isn’t on an exchange? Here’s the straight answer, what the company does, whether it’s public, and the realistic ways investors can get exposure.
What is Neuralink?
Neuralink is a brain-computer interface company founded in 2016 and based in the United States. Its stated goal is to build a “generalized input/output platform for the brain,” starting with Telepathy, a product designed to help people with paralysis control computers, phones, and robotic limbs using thought alone. The company also says it is working on vision restoration and speech restoration programs.
Neuralink does not publicly disclose revenue, so there is no clean way to size the business on sales today. What is visible is the clinical footprint: the company says it has trials in multiple geographies and has named clinical partners including Barrow Neurological Institute, The Miami Project / University of Miami, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi. Public estimates of headcount vary, with one estimate putting it at 705 employees as of July 20, 2026 and another at 469 as of March 2026, but those figures should be treated cautiously.
Is Neuralink publicly traded?
No, Neuralink is currently a privately held company and does not trade on a public exchange. Its website and legal terms identify the operating company as Neuralink Corp., and there is no public ticker or evidence of a public parent company.
That means retail investors cannot buy Neuralink shares through a standard brokerage account today. Ownership appears to remain private and founder-controlled, with Elon Musk as founder and the company still outside the public markets.
When will Neuralink go public?
There is no S-1 filing for Neuralink on SEC EDGAR, and Neuralink has not publicly announced an IPO timetable in the sources reviewed. The company’s public messaging has focused on clinical progress and private fundraising rather than a near-term listing.
The latest confirmed financing was a $650 million Series E announced June 2, 2025. Neuralink did not disclose a valuation in its own announcement, even though earlier reporting suggested the company was seeking money at an $8.5 billion pre-money valuation and later raised capital at a $9 billion pre-money valuation. For now, the clearest read is that Neuralink remains private and any IPO would depend on clinical milestones, regulatory progress, and management’s timing.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
For most retail investors, the first option is simple: wait for an IPO. If Neuralink ever files, you would typically be able to buy shares through a regular brokerage account once trading begins, but there is no public timetable today.
There is no public parent stock to buy instead, because Neuralink is not a subsidiary of a listed company. The practical public-market alternative is to look at comparable medical-device and neuromodulation names that trade on exchanges. If you want direct private-company exposure before an IPO, private secondary markets can sometimes offer access, but those venues are generally limited to accredited investors and availability is not guaranteed.
The honest answer is that most retail investors will not get direct ownership of Neuralink today. If you want exposure now, the better path is to study the closest public peers and accept that they are proxies, not substitutes.
Indirect exposure: backdoor ways to invest
ARK Venture Fund disclosed Neuralink as a holding, and ARK said that as of April 30, 2026, Neuralink was its 12th largest holding at about 2.12% weighting. That gives investors one indirect route to private-company exposure, but it is a venture fund, not a direct Neuralink share.
The catch is dilution and access. Buying a fund with Neuralink in it does not give you direct ownership of Neuralink, just a slice of a broader portfolio. I did not find a confirmed public ETF holding Neuralink directly in the sources reviewed, and I did not find evidence that mainstream mutual funds had publicly disclosed a Neuralink stake.
Closest publicly-traded alternatives
The closest public comps are Medtronic (MDT), Abbott (ABT), and Boston Scientific (BSX). Medtronic is a useful proxy because of its broad neuromodulation and implantable-device exposure. Abbott is relevant for its regulated medical-device platform and neuromodulation footprint. Boston Scientific is another large implantable-device company with adjacent neuromodulation and medical-technology exposure.
These are not true brain-computer-interface peers, but they are the public stocks investors usually look at when they want exposure to implantable neurotech commercialization. If you are trying to invest in Neuralink and can’t, these are the names most likely to come up as market proxies.
Recent news
Neuralink’s biggest recent development was its $650 million Series E on June 2, 2025. The company said the round included ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, and Vy Capital, among others.
Since then, the company has kept pushing clinical milestones: on January 28, 2026 it said it had 21 participants in its program, and on July 31, 2025 it announced the GB-PRIME study launch in Great Britain. Reuters also reported in September 2025 that Neuralink planned a speech-impairment trial and had received FDA Breakthrough Device designation for speech.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
If you want Neuralink specifically, the answer is blunt: you can’t buy it in a normal brokerage account right now. There is no public ticker, no IPO filing, and no public parent stock to use as a shortcut.
The realistic move for retail investors is to watch for a future IPO and, in the meantime, use public proxies like MDT, ABT, and BSX if you want exposure to the broader implantable neuro/medical-device theme. Accredited investors can also look at private secondary markets or venture funds, but those are limited, less liquid, and not guaranteed to offer access.
▌Common Questions
Frequently asked questions
+Is Neuralink publicly traded?
No, Neuralink is currently a privately held company and does not trade on a public exchange. Its website and legal terms identify the operating company as Neuralink Corp., and there is no public ticker or evidence of a public parent company.
+When will Neuralink go public?
There is no S-1 filing for Neuralink on SEC EDGAR, and Neuralink has not publicly announced an IPO timetable in the sources reviewed. The company’s public messaging has focused on clinical progress and private fundraising rather than a near-term listing.
+How can you invest in Neuralink?
For most retail investors, the first option is simple: wait for an IPO. If Neuralink ever files, you would typically be able to buy shares through a regular brokerage account once trading begins, but there is no public timetable today.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
